Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PainChek has appointed Pete Shergill as the Head of Business Development for the company’s U.K. business
  • Pete is a qualified pharmacist with over 20 years experience
  • Painchek is currently expanding its smartphone technology into the U.K
  • The technology helps children and adults suffering various types of pain to better manage it

PainChek has appointed Pete Shergill as the Head of Business Development for the company’s U.K. business.

Painchek U.K. has recently been registered as a U.K. company and will be a subsidiary of PainChek.

Pete is a qualified pharmacist and has over 20 years experience in the U.K. health and software industry. He has held several leadership roles at Lloyd’s Pharmacy, Celesio U.K., iCareHealth U.K., and The Access Group.

CEO Philip Daffas is pleased to have Pete as part of the team.

“Pete brings the knowledge, experience and capability to accelerate the PainChek U.K. business, working with our channel partners in aged care and building our business directly into the hospital and home care market segments,” he said.

PainChek is an Australian based company that develops pain assessment technologies on a smartphone.

The smartphone technology records a short video of the user’s face, analyses the images that indicate pain and then records the data. The technology will then calculate an overall pain score, which allows the caregiver to monitor the effect of medication and treatment over time.

PainChek has two apps targeting different groups. One is for adults who are unable to verbalise their pain, such as patients suffering dementia.

The other app is for children who have not yet learnt to communicate.

There are more than 700,000 people living with dementia in the U.K. and this figure is estimated to grow to 850,000 by 2021.

The demand for better dementia care within aged care facilities continues to increase as two thirds (around 300,000) of the 500,000 residents are living with dementia across more than 10,000 U.K. aged care and nursing homes.

“The consensus of client feedback confirms a very clear clinical need and economic rationale for PainChek within the UK Aged Care and Nursing Home sector,” Philip added.

Earlier this year, the Australian government invested $5 million in the Adult App for aged care facilities. The app is now used in more than 150 residential aged care homes across Australia.

It was also recently announced Painchek will be collaborating with Murdoch Children’s Research Institution to clinically test a version of PainChek App for children.

More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.